PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25944854-2	2015	The ASSERTIVE study previously reported more sustained control of Br-SBP with aliskiren versus telmisartan in patients with hypertension, following 7-days treatment withdrawal.	aliskiren	78-87	selenium binding protein 1	Homo sapiens	69-72	
30631130-7	2019	Aliskiren induced slightly greater DBP and SBP reductions than other antihypertensive agents (WMD -0.77 mmHg, 95% CI [-2.01;0.46 mmHg] and WMD -1.14 mmHg, 95% CI [-2.78;0.50 mmHg], respectively).	aliskiren	0-9	selenium binding protein 1	Homo sapiens	43-46	
25944854-9	2015	CONCLUSIONS: Following treatment withdrawal, aliskiren demonstrated more sustained control of both brachial and central SBP than telmisartan.	aliskiren	45-54	selenium binding protein 1	Homo sapiens	120-123	
28348679-6	2012	Mean reduction in sBP and dBP with aliskiren 150 mg/d was 6.7 +- 5.4 mmHg and 5.4 +- 4.8 mmHg, respectively.	aliskiren	35-44	selenium binding protein 1	Homo sapiens	18-21	
28348679-7	2012	Mean reduction in sBP and dBP with aliskiren 300 mg/d was 8.6 +- 6.3 mmHg and 6.0 +- 4.9 mmHg, respectively.	aliskiren	35-44	selenium binding protein 1	Homo sapiens	18-21	
19158826-6	2009	Aliskiren 300 mg significantly lowered both SBP -3.0 (-4.0, -2.0) and DBP -1.7 (-2.3, -1.0) as compared to aliskiren 150 mg. Aliskiren has no effect on blood pressure variability.	aliskiren	0-9	selenium binding protein 1	Homo sapiens	44-47	
22157325-11	2012	In this uncontrolled, high-risk treated hypertensive population, SBP and DBP levels recorded during treatment with aliskiren were consistently lower than those recorded at entry visits in a context of a very low rate of reported side-effects.	aliskiren	115-124	selenium binding protein 1	Homo sapiens	65-68	
21124333-6	2011	After 8 weeks, aliskiren treatments reduced systolic blood pressure (SBP) from 169.0+-20.1 to 153.7+-19.6 mmHg (P<0.001) and diastolic blood pressure (DBP) from 78.1+-12.0 to 73.0+-13.6 mmHg (P=0.048).	aliskiren	15-24	selenium binding protein 1	Homo sapiens	69-72	
20814848-5	2010	Both aliskiren and losartan induced a significant and similar SBP/DBP reduction (-15.6/10.7 mmHg and -15.5/10.5 mmHg, p<0.001 vs. baseline, respectively).	aliskiren	5-14	selenium binding protein 1	Homo sapiens	62-65	
22441345-5	2012	From EoA to day 7 of treatment withdrawal (end of withdrawal, EoW), the least squares mean increase in 24-h mean ambulatory SBP was smaller for aliskiren (2.7 mmHg) vs. telmisartan (6.5  mmHg).	aliskiren	144-153	selenium binding protein 1	Homo sapiens	124-127	
18843743-18	2008	Aliskiren 300 mg significantly lowered both SBP and DBP as compared to aliskiren 150 mg (SBP:-2.97 (95% CI -3.99, -1.95) and DBP: -1.66 (95% CI -2.32, -1.0).	aliskiren	0-9	selenium binding protein 1	Homo sapiens	44-47	
18843743-18	2008	Aliskiren 300 mg significantly lowered both SBP and DBP as compared to aliskiren 150 mg (SBP:-2.97 (95% CI -3.99, -1.95) and DBP: -1.66 (95% CI -2.32, -1.0).	aliskiren	0-9	selenium binding protein 1	Homo sapiens	89-92